Opinion|Videos|October 31, 2024
Generalized Myasthenia Gravis Classification and Treatment Strategy
Key Takeaways
- gMG classification considers clinical presentation, antibody status, and disease severity to guide treatment strategies.
- The MGFA clinical classification system categorizes patients from Class I (ocular symptoms) to Class V (intubation required).
Panelists discuss how the classification of generalized myasthenia gravis (gMG) informs and guides treatment strategies for patients.
Advertisement
Video content above is prompted by the following:
- How do you classify gMG, and how does this guide your treatment strategy?
Advertisement
Related to this article
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
A published protocol outlines the randomized, open-label EPOCH trial testing whether cilostazol accelerates hematoma resorption and improves recovery after intracerebral hemorrhage.
Brian Lin, PhD, discussed the current evidence linking football participation with ALS, the questions that remain unanswered, and how emerging research may help clarify the association.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes]
A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
In honor of Muscular Dystrophy Awareness Month, held annually in September, NeurologyLive® looks back at the decade-long expansion of the DMD treatment landscape and the data that supports each approval.
Marketed as Fayuvi, the 1-time AAV9 gene therapy showed sustained cerebrospinal fluid heparan sulfate drops and developmental gains among pediatric patients with mucopolysaccharidosis type IIIA in prior studies.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
2
FDA Clears Phase 1b/2 Trial of CAR T-Cell Therapy C-CAR168 for Refractory Progressive Multiple Sclerosis
3
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
4
Episode 175: Advancing the Ways of Treating Cluster Headache
5